GlaxoSmithKline plc (GSK) Shares Bought by Brown Advisory Inc.
Brown Advisory Inc. boosted its holdings in GlaxoSmithKline plc (NYSE:GSK) by 15.4% during the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 113,358 shares of the pharmaceutical company’s stock after acquiring an additional 15,117 shares during the quarter. Brown Advisory Inc.’s holdings in GlaxoSmithKline were worth $4,603,000 at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors have also made changes to their positions in the business. Renaissance Technologies LLC grew its position in GlaxoSmithKline by 112.1% during the 2nd quarter. Renaissance Technologies LLC now owns 9,338,000 shares of the pharmaceutical company’s stock worth $402,655,000 after acquiring an additional 4,935,900 shares during the last quarter. FMR LLC grew its position in GlaxoSmithKline by 5.9% during the 2nd quarter. FMR LLC now owns 25,024,276 shares of the pharmaceutical company’s stock worth $1,079,047,000 after acquiring an additional 1,389,238 shares during the last quarter. Federated Investors Inc. PA grew its position in GlaxoSmithKline by 22.7% during the 2nd quarter. Federated Investors Inc. PA now owns 4,511,155 shares of the pharmaceutical company’s stock worth $194,521,000 after acquiring an additional 833,501 shares during the last quarter. Marshall Wace North America L.P. grew its position in GlaxoSmithKline by 148.0% during the 2nd quarter. Marshall Wace North America L.P. now owns 1,119,491 shares of the pharmaceutical company’s stock worth $48,138,000 after acquiring an additional 668,088 shares during the last quarter. Finally, Seatown Holdings Pte. Ltd. bought a new position in GlaxoSmithKline during the 3rd quarter worth approximately $20,148,000. Institutional investors and hedge funds own 9.83% of the company’s stock.
Several research firms recently issued reports on GSK. UBS upgraded GlaxoSmithKline from a “neutral” rating to a “buy” rating and raised their price target for the stock from $35.04 to $35.85 in a research report on Monday, November 27th. Argus restated a “buy” rating and set a $50.00 price target on shares of GlaxoSmithKline in a research report on Thursday, August 31st. Zacks Investment Research lowered GlaxoSmithKline from a “buy” rating to a “hold” rating in a research report on Tuesday, October 24th. Bank of America lowered GlaxoSmithKline from a “buy” rating to a “neutral” rating in a research report on Thursday, October 26th. Finally, J P Morgan Chase & Co restated a “neutral” rating on shares of GlaxoSmithKline in a research report on Thursday, September 14th. Three research analysts have rated the stock with a sell rating, ten have assigned a hold rating and six have given a buy rating to the stock. GlaxoSmithKline currently has a consensus rating of “Hold” and an average target price of $39.71.
GlaxoSmithKline plc (NYSE GSK) traded down $0.14 during midday trading on Wednesday, reaching $34.72. The company’s stock had a trading volume of 1,896,296 shares, compared to its average volume of 3,498,092. GlaxoSmithKline plc has a 1-year low of $34.72 and a 1-year high of $44.53. The company has a current ratio of 0.64, a quick ratio of 0.44 and a debt-to-equity ratio of 2.96. The stock has a market cap of $86,076.94, a PE ratio of 12.41, a P/E/G ratio of 1.94 and a beta of 0.98.
The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, January 11th. Shareholders of record on Friday, November 10th will be issued a $0.5037 dividend. The ex-dividend date is Thursday, November 9th. This represents a $2.01 annualized dividend and a yield of 5.80%. This is a boost from GlaxoSmithKline’s previous quarterly dividend of $0.49. GlaxoSmithKline’s dividend payout ratio (DPR) is 163.12%.
In other news, major shareholder Plc Glaxosmithkline bought 428,571 shares of the stock in a transaction dated Monday, November 6th. The stock was bought at an average price of $14.00 per share, for a total transaction of $5,999,994.00. The purchase was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Company insiders own 10.00% of the company’s stock.
TRADEMARK VIOLATION NOTICE: This piece of content was originally posted by Watch List News and is the sole property of of Watch List News. If you are viewing this piece of content on another domain, it was stolen and reposted in violation of U.S. & international copyright & trademark laws. The correct version of this piece of content can be accessed at https://www.watchlistnews.com/glaxosmithkline-plc-gsk-shares-bought-by-brown-advisory-inc/1747559.html.
GlaxoSmithKline Company Profile
GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.
Want to see what other hedge funds are holding GSK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GlaxoSmithKline plc (NYSE:GSK).
Receive News & Ratings for GlaxoSmithKline plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline plc and related companies with Analyst Ratings Network's FREE daily email newsletter.